Prognostic value of tissue vascular endothelial growth factor expression in bladder cancer: A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 2, 2013, Pages 645-649

  Huang, Yu Jing ^a   Qi, Wei Xiang ^a   He, Ai Na ^a   Sun, Yuan Jue ^a   Shen, Zan ^a   Yao, Yang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Bladder cancer; Meta analysis; Prognosis; Vascular endothelial growth factor

Indexed keywords

TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; BIOSYNTHESIS; BLADDER TUMOR; DISEASE FREE SURVIVAL; GENE EXPRESSION; HUMAN; META ANALYSIS; METABOLISM; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); SURVIVAL; TREATMENT OUTCOME;

AGED; DISEASE-FREE SURVIVAL; GENE EXPRESSION; HUMANS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; SURVIVAL; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84877641621     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.2.645     Document Type: Article

References (34)

1. Bernardini S, Fauconnet S, Chabannes E, et al (2001). Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol, 166, 1275-9.
2. Chen J, Li T, Wu Y, et al (2011). Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis. J Cancer Res Clin Oncol, 137, 1799-812.
3. Crew JP, O'Brien T, Bradburn M, et al (1997). Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res, 57, 5281-5.
4. DerSimonian Rand Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
5. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
6. Ferrara N (2004). Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev, 25, 581-611.
7. Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1, 27-31.
8. Hanahan Dand Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-74.
9. Herrmann E, Eltze E, Bierer S, et al (2007). VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer: relationships to clinicopathological parameters and long-term survival. Anticancer Res, 27, 3127-33.
10. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
11. Inoue K, Slaton JW, Karashima T, et al (2000). The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res, 6, 4866-73.
12. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
13. Kanda S, Miyata Y and Kanetake H (2006). Current status and perspective of antiangiogenic therapy for cancer: urinary cancer. Int J Clin Oncol, 11, 90-107.
14. Li Z, Qi F, Qi L, et al (2011). VEGF-C as a decision-making biomarker for selected patients with invasive bladder cancer who underwent bladder-preserving radical surgery. Arch Med Res, 42, 405-11.
15. Ma Y, Hou Y, Liu B, et al (2010). Intratumoral lymphatics and lymphatic vessel invasion detected by D2-40 are essential for lymph node metastasis in bladder transitional cell carcinoma. Anat Rec (Hoboken), 293, 1847-54.
16. Nadaoka J, Horikawa Y, Saito M, et al (2008). Prognostic significance of HIF-1 alpha polymorphisms in transitional cell carcinoma of the bladder. Int J Cancer, 122, 1297-302.
17. Parmar MK, Torri V and Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.
18. Pignot G, Bieche I, Vacher S, et al (2009). Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker. Eur Urol, 56, 678-88.
19. Qu JT, Wang M, He HL, et al (2012). The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review. J Cancer Res Clin Oncol, 138, 819-25.
20. Schoenleber SJ, Kurtz DM, Talwalkar JA, et al (2009). Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer, 100, 1385-92.
21. Shariat SF, Youssef RF, Gupta A, et al (2010). Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol, 183, 1744-50.
22. Suzuki K, Morita T and Tokue A (2005). Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. Int J Urol, 12, 152-8.
23. Szarvas T, Jager T, Droste F, et al (2009). Serum levels of angiogenic factors and their prognostic relevance in bladder cancer. Pathol Oncol Res, 15, 193-201.
24. Szarvas T, Jager T, Totsch M, et al (2008). Angiogenic switch of angiopietins-Tie2 system and its prognostic value in bladder cancer. Clin Cancer Res, 14, 8253-62.
25. Theodoropoulos VE, Lazaris A, Sofras F, et al (2004). Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol, 46, 200-8.
26. Thieblemont C, Fendler JP, Trillet-Lenoir V, et al (1996). [Prognostic factors of survival in infiltrating urothelial bladder carcinoma. A retrospective study of 158 patients treated by radical cystectomy]. Bull Cancer, 83, 139-46.
27. van Rhijn BW (2012). Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer. Urol Oncol, 30, 518-23.
28. Wells GA, Brodsky L, O'Connell D, et al (2003). An Evaluation of the Newcastle Ottawa Scale: An Assessment Tool for Evaluating the Quality of Non-Randomized Studies. In XI Cochrane Colloquium Vol. O-63. p 26. Barcelona: XI International Cochrane Colloquium Book of Abstracts.
29. Yang CC, Chu KC and Yeh WM (2004). The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol, 22, 1-6.
30. Youssef RFand Lotan Y (2011). Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer. ScientificWorldJournal, 11, 369-81.
31. Yu L, Deng L, Li J, et al (2012). The prognostic value of vascular endothelial growth factor in ovarian cancer: A systematic review and meta-analysis. Gynecol Oncol, 128, 391-6.
32. Zaravinos A, Volanis D, Lambrou GI, et al (2012). Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder. Oncol Rep, 28, 1159-66.
33. Zhan P, Wang J, Lv XJ, et al (2009). Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol, 4, 1094-103.
34. Zu X, Tang Z, Li Y, et al (2006). Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. BJU Int, 98, 1090-3.